Abcuro secures $66 million to advance Phase 3 trial in milder form of muscle disease
Abcuro raised $66 million to fund a Phase 3 study after its sole drug failed overall in a muscle-weakening condition but showed promise in patients with less severe disease. The company plans to focus on that subgroup in the upcoming trial. CEO Alex indicated the funding will support the late-stage development.
Related stories
Definium Therapeutics' oral LSD candidate succeeds in initial Phase 3 trial for generalized anxiety disorder · Mental health
Argenx's subcutaneous therapy meets late-stage goal in rare muscle disease, with subgroup miss · Drug development
Eyepoint's wet AMD therapy misses key endpoint in trial · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Abcuro gets $66M for Phase 3 in muscle-weakening condition.” Browse more stories.